natgillin/translations-raw huggingface dataset:
One was obtained by hydroxylation of the pyrrolidone ring (1.6 % of the dose) and the other one by opening of the pyrrolidone ring (0.9 % of the dose). 
Jedan nastaje hidroksilacijom pirolidonskog prstena (1,6% doze), a drugi otvaranjem pirolidonskog prstena (0,9% doze).
You should not drive or use machines until it is established that your ability to perform such activities is not affected. 
Ne smijete voziti ili upravljati strojevima dok se ne utvrdi da nije smanjena Vaša sposobnost za provođenje tih aktivnosti.
< 1/100); rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000). 
<1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). 
Levetiracetam se koristi za oblik epilepsije u kojem napadaji započinju u jednoj strani mozga, ali se nakon toga mogu proširiti na veća područja u obje strane mozga (parcijalni napadaj sa ili bez sekundarne generalizacije).
C/C, n. 4, Poligono Industrial Malpica 50016 Zaragoza 
4, Poligono Industrial Malpica 50016 Zaragoza
Example: if your daily dose is 1,000 mg, you might take 2 tablets of 250 mg in the morning and 2 tablets of 250 mg in the evening. 
Na primjer: ako je Vaša dnevna doza 1000 mg, mogli biste uzeti 2 tablete od 250 mg ujutro i 2 tablete od 250 mg navečer.
• A small number of people being treated with anti-epileptics such as Levetiracetam Teva have had thoughts of harming or killing themselves. 
• Mali broj ljudi liječenih antiepilepticima kao što je Levetiracetam Teva imali su misli o samoozljeđivanju ili samoubojstvu.
In addition it partially reverses the reductions in GABA- and glycine-gated currents induced by zinc and β-carbolines. 
Također djelomično poništava smanjenje GABA- i glicin-posredovanih protoka inducirano cinkom i β-karbolinima.
Other medicines and Levetiracetam Teva 
Drugi lijekovi i Levetiracetam Teva
Do not take macrogol (a drug used as laxative) for one hour before and one hour after taking levetiracetam as this may results in a loss of its effect. 
Ne uzimajte makrogol (lijek koji se koristi kao laksativ) jedan sat prije i jedan sat nakon uzimanja levetiracetama zbog toga što se može smanjiti učinak levetiracetama.
• If you are allergic to levetiracetam, pyrrolidone derivatives or any of the other ingredients of this medicine (listed in Section 6). 
• Ako ste alergični na levetiracetam, derivate pirolidona ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.).
Contents of the pack and other information What Levetiracetam Teva contains 
Sadržaj pakiranja i druge informacije Što Levetiracetam Teva sadrži
- The active substance is levetiracetam. 
- Djelatna tvar je levetiracetam.
Talk to your doctor before taking Levetiracetam Teva 
Obratite se svom liječniku prije nego uzmete Levetiracetam Teva:
ks = 0.45 in Term infants to 1 year old; ks = 0.55 in Children to less than 13 years and in adolescent female; ks = 0.7 in adolescent male 
ks = 0,45 za dojenčad do 1. godine života rođene u terminu; ks = 0,55 za djecu mlađu od 13 godina i za adolescente ženskog spola; ks = 0,7 za adolescente muškog spola
• If you notice any slow down in the growth or unexpected puberty development of your child, please contact your doctor. 
• Ako primijetite usporen rast ili neočekivan razvoj djeteta u pubertetu, obavijestite svog liječnika;
The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 
Urez služi samo kako bi se olakšalo lomljenje tablete radi lakšeg gutanja, a ne da bi se podijelila na jednake doze.
After an acute overdose, the stomach may be emptied by gastric lavage or by induction of emesis. 
Nakon akutnog predoziranja, želudac se može isprazniti gastričnom lavažom ili izazivanjem povraćanja.
When you will first start taking Levetiracetam Teva, your doctor will prescribe you a lower dose (500 mg each day) during 2 weeks before giving you the lowest general dose of 1,000 mg. 
Kad prvi put počnete uzimati Levetiracetam Teva, liječnik će Vam propisati manju dozu (500 mg svaki dan) tijekom 2 tjedna prije davanja najmanje uobičajene doze od 1000 mg.
What Levetiracetam Teva looks like and contents of the pack 
Kako Levetiracetam Teva izgleda i sadržaj pakiranja
• elevated/abnormal values in a liver function test; 
• povišene/promijenjene vrijednosti testova jetrene funkcije;
Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). 
Levetiracetam je antiepileptik (lijek koji se koristi u liječenju epileptičkih napadaja).
Swallow Levetiracetam Teva tablets with a sufficient quantity of liquid (e.g. a glass of water). 
Progutajte Levetiracetam Teva tablete s dovoljnom količinom tekućine (npr. s čašom vode).
Prevalence is significantly higher in Japanese patients when compared to non-Japanese patients. 
Prevalencija je značajno veća u japanskih bolesnika u usporedbi s bolesnicima koji nisu japanskog podrijetla.
How to store Levetiracetam Teva Contents of the pack and other information 
Kako čuvati Levetiracetam Teva Sadržaj pakiranja i druge informacije
Therefore, caution is recommended in those patients when performing skilled tasks, e.g. driving vehicles or operating machinery. 
Stoga je kod takvih bolesnika potreban oprez kada obavljaju poslove koji zahtijevaju vještinu kao što je upravljanje vozilima i strojevima.
Should your doctor decide to stop your Levetiracetam Teva treatment, he/she will instruct you about the gradual withdrawal of Levetiracetam Teva. 
Ako Vaš liječnik odluči prekinuti liječenje Levetiracetamom Teva, uputit će Vas kako postupno prekinuti liječenje Levetiracetamom Teva.
However, if levetiracetam treatment is needed during breast-feeding, the benefit/risk of the treatment should be weighed considering the importance of breast-feeding. 
Međutim, ako je liječenje levetiracetamom potrebno tijekom dojenja, treba procijeniti omjer koristi i rizika liječenja uzimajući u obzir važnost dojenja.
Infants and children (1 month to 4 years) 
Dojenčad i djeca (1 mjesec do 4. godine)
Hypersensitivity to the active substance or other pyrrolidone derivatives or to any of the excipients listed in section 6.1. 
Preosjetljivost na djelatnu tvar ili neke druge pirolidonske derivate ili neku od pomoćnih tvari navedenih u dijelu 6.1.
• a more severe form of rash causing skin peeling in more than 30 % of the body surface (toxic epidermal necrolysis) 
• puno teži oblik osipa koji uzrokuje ljuštenje kože u više od 30 % površine tijela (toksična epidermalna nekroliza)
A meta-analysis of randomized placebo-controlled trials of anti-epileptic medicinal products has shown a small increased risk of suicidal thoughts and behaviour. 
Metaanaliza randomiziranih placebom kontroliranih studija antiepileptičkih lijekova pokazala je mali porast rizika od samoubilačkih misli i ponašanja.
• Levetiracetam Teva is not indicated in children and adolescents below 16 years on its own (monotherapy). 
• Levetiracetam Teva nije indiciran u djece i adolescenata mlađih od 16 godina kao samostalni lijek (monoterapija).
74770 Opava-Komarov Czech Republic 
74770 Opava-Komarov
There have been isolated reports of decreased levetiracetam efficacy when the osmotic laxative macrogol has been concomitantly administered with oral levetiracetam. 
Postoje izolirane prijave smanjenja djelotvornosti levetiracetama kada se osmotski laksativ makrogol istodobno primjenjuje s oralnim levetiracetamom.
Do not use this medicine after the expiry date stated on the carton box and blister after EXP. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru iza oznake „EXP“.
Depending upon the clinical response and tolerability, the daily dose can be increased up to 1500 mg twice daily. 
Ovisno o kliničkom odgovoru i podnošljivosti lijeka, dnevna doza može se povećati do 1500 mg dva puta na dan.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Outer carton 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK United Kingdom 
TEVA UK Ltd Brampton Road Hampden Park Eastbourne, East Sussex BN22 9AG UK Ujedinjeno Kraljevstvo
However, long term effects on learning, intelligence, growth, endocrine function, puberty and childbearing potential in children remain unknown. 
nisu poznati dugoročni učinci kod djece na učenje, inteligenciju, rast, endokrinu funkciju, pubertet i reproduktivnu sposobnost.
The pharmacokinetic results indicated that half-life was shorter (5.3 h) than for adults (7.2 h) and apparent clearance was faster (1.5 ml/min/kg) than for adults (0.96 ml/min/kg). 
Farmakokinetički podaci ukazuju da je poluvijek života (5,3 h) kraće nego u odraslih (7,2 h), a prividni klirens (1,5 ml/min/kg) brži je nego u odraslih (0,96 ml/min/kg).
The starting dose for a child or adolescent of 25 kg should be 250 mg twice daily with a maximum dose of 750 mg twice daily. 
Početna doza za dijete ili adolescenta od 25 kg treba biti 250 mg dva puta na dan, uz maksimalnu dozu od 750 mg dva puta na dan.
Dose and frequency(1) Infants 1 to less than 6 months 
Doza i učestalost primjene (1) Dojenčad od 1 do manje od 6 mjeseci
• on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. 
• samostalno u odraslih i adolescenata od 16. godine života s novodijagnosticiranom epilepsijom, u liječenju određenog oblika epilepsije.
• a skin rash which may form blisters and look like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge) (erythema multiforme) 
• crvenilo kože koje može tvoriti mjehure i izgledati kao male mete (sa središnjim tamnim točkama okruženim bljeđim područjem i tamnim prstenom oko ruba) (erythema multiforme),
Read all of this leaflet carefully before you or your child start taking this medicine because it contains important information for you. 
Vi ili Vaše dijete počnete uzimati ovaj lijek jer sadrži
Results related to behavioural and emotional functioning indicated a worsening in levetiracetam treated patients on aggressive behaviour as measured in a standardised and systematic way using a validated instrument (CBCL - Achenbach Child Behaviour Checklist). 
Rezultati ocjene funkcioniranja ponašanja i emocionalnog funkcioniranja uputili su na pogoršanje u smislu agresivnijeg ponašanja u skupini koja je uzimala levetiracetam, ocijenjenog na standardiziran i sistematičan način koristeći validirani instrument (CBCL - Achenbach Child Behavior Checklist).
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction 
• slabost, osjećaj ošamućenosti ili vrtoglavice ili poteškoće s disanjem, budući da to mogu biti znakovi ozbiljne alergijske (anafilaktičke) reakcije
These data are supplemented with the use of levetiracetam in corresponding open-label extension studies, as well as post-marketing experience. 
Ti podaci dopunjeni su podacima iz odgovarajućih ispitivanja otvorenog produžetka o primjeni levetiracetama, kao i iskustvima nakon stavljanja lijeka u promet.
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1-pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Djelatna tvar, levetiracetam, jest derivat pirolidona (S-enantiomer α-etil-2-okso-1-pirolidin acetamida), kemijski različit od postojećih antiepileptičkih djelatnih tvari.
Six-month seizure freedom was achieved in 73.0 % of levetiracetam-treated patients and 72.8 % of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2 % (95 % CI: -7.8 8.2). 
73,0% bolesnika liječenih levetiracetamom i 72,8% bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2% (95% CI: -7,8 8,2).
In both these paediatric age ranges, these data are supplemented with the post-marketing experience of the use of levetiracetam. 
U obje od tih pedijatrijskih dobnih skupina, ti podaci dopunjeni su iskustvom primjene levetiracetama nakon stavljanja lijeka u promet.
Levetiracetam Teva is used: 
Levetiracetam Teva se koristi:
The risk of anorexia is higher when levetiracetam is coadministered with topiramate. 
Rizik anoreksije veći je ako se levetiracetam uzima istodobno s topiramatom.
Levetiracetam Teva is indicated as adjunctive therapy 
Levetiracetam Teva je indiciran kao dodatna terapija:
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2). 
U bolesnika s teško oštećenom jetrenom funkcijom treba odrediti funkciju bubrega prije odabira doze (vidjeti dio 4.2).
At 3600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri dozi od 3600 mg/kg/dan samo je u jednoj od dvije EFD studije uočeno blago smanjenje fetalne težine povezano s marginalnim porastom varijacija kostura/malih anomalija.
What you need to know before you take Levetiracetam Teva Do not take Levetiracetam Teva 
Što morate znati prije nego počnete uzimati Levetiracetam Teva
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na početku liječenja ili nakon povećanja doze, nuspojave poput pospanosti, umora i omaglice, mogu se javiti češće.
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Profil nuspojava opisan niže temelji se na analizi objedinjenih placebom konroliranih kliničkih istraživanja za sve ispitivane indikacije, u kojima je levetiracetamom liječeno ukupno 3416 bolesnika.
Epilepsy is a condition where the patients have repeated fits (seizures). 
Epilepsija je stanje u kojem bolesnici imaju ponavljane epileptičke napadaje.
This medicine contains less than 1 mmol sodium (23 mg) per film-coated tablet that is to say essentially `sodium-free ´. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po filmom obloženoj tableti, tj. zanemarive količine natrija.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behaviour were not worse than baseline. 
Međutim, u ispitanika koji su uzimali levetiracetam tijekom dugoročne, otvorene studije provedene praćenjem u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja, osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma. 
Štetni učinci s mogućim značajem za kliničku primjenu koji nisu primijećeni tijekom kliničkih studija, a koji su nađene kod štakora i u manjoj mjeri kod miševa izloženih razinama sličnim razinama izloženosti kod ljudi, bili su promjene jetre koje su upućivale na prilagodbeni odgovor, kao na primjer povećana težina i centrilobularna hipertrofija, masna infiltracija jetre i povišene razine jetrenih enzima u plazmi.
The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. 
Preporučena početna doza je 250 mg dva puta na dan, koju nakon dva tjedna treba povećati do inicijalne terapijske doze od 500 mg dva puta na dan.
• Dose in adults and adolescents (from 16 years of age): 
• Doza za odrasle i adolescente (od 16. godine života)
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/kg twice daily every two weeks). 
Ako treba prekinuti liječenje levetiracetamom, preporučuje se postupni prekid (npr. u odraslih i adolescenata tjelesne težine veće od 50 kg: smanjenje za 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata tjelesne težine manje od 50 kg: smanjenje doze ne smije biti veće od 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69). 
U studiji, koja je bila odraz kliničke prakse, bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od
If you stop taking Levetiracetam Teva 
Ako prestanete uzimati Levetiracetam Teva
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to 
Nuspojave su navedene redoslijedom od ozbiljnijih prema manje ozbiljnima i njihova je učestalost definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i
Creatinine clearance (ml/min/1.73 m2) 
Klirens kreatinina (ml/min/1,73m2)
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. 
Levetiracetam ne utječe na glukuronidaciju valproatne kiseline in vitro.
The daily dose must be individualised according to renal function. 
Dnevna doza mora se odrediti za svakog bolesnika pojedinačno u skladu s bubrežnom funkcijom.
Each Levetiracetam Teva 250, 500, 750, 1,000 mg film-coated tablet contains 250, 500, 750, 1,000 mg levetiracetam. 
Jedna Levetiracetam Teva 250, 500, 750, 1000 mg filmom obložena tableta sadrži 250, 500, 750, 1000 mg levetiracetama.
20 film-coated tablets 30 film-coated tablets 50 film-coated tablets 50x1 film-coated tablet 60 film-coated tablets 100 film-coated tablets 120 film-coated tablets 200 film-coated tablets 
20 filmom obloženih tableta 30 filmom obloženih tableta 50 filmom obloženih tableta 50x1 filmom obložena tableta 60 filmom obloženih tableta 100 filmom obloženih tableta 120 filmom obloženih tableta 200 filmom obloženih tableta
In a pooled analysis, the percentage of patients who achieved 50 % or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7 %, 31.6 % and 41.3 % for patients on 1000, 2000 or 3000 mg levetiracetam respectively and of 12.6 % for patients on placebo. 
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50%-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7% kod uzetih 1000 mg, 31,6% kod uzetih 2000 mg i 41,3% kod uzetih 3000 mg levetiracetama te 12,6% kod uzimanja placeba.
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]) 
• simptome nalik gripi i osip na licu popraćen proširenim osipom s visokom tjelesnom temperaturom, povećane vrijednosti jetrenih enzima u krvnim testovima, povećanje posebne vrste bijelih krvnih stanica (eozinofilija) i povećane limfne čvorove (reakcija na lijek s eozinofilijom i sistemskim simptomima [DRESS])
Alopecia, eczema, pruritus, 
Alopecija, ekcem, pruritis
Levetiracetam Teva 750 mg contains Sunset Yellow 
Levetiracetam Teva 750 mg sadrži sunset yellow
The patients were randomized to carbamazepine CR 400 - 1200 mg/day or levetiracetam 1000 - 3000 mg/day, the duration of the treatment was up to 121 weeks depending on the response. 
Bolesnici su randomizirani za dobivanje 400 -1200 mg karbamazepina s kontroliranim otpuštanjem (CR) na dan ili 1000 -3000 mg levetiracetama na dan, liječenje je trajalo do 121 tjedna, ovisno o odgovoru.
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 AND UGT1A6) and epoxide hydroxylase activities. 
In vitro je pokazano da levetiracetam i njegov glavni metabolit ne inhibiraju aktivnost glavnih izoformi humanog citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 i 1A2), glukuronil transferaze
• nasopharyngitis; 
• nazofaringitis;
Tablet core: maize starch, povidone, croscarmellose sodium and magnesium stearate. 
Jezgra tablete: kukuruzni škrob, povidon, umrežena karmelozanatrij i magnezijev stearat.
Levetiracetam 1,000 mg daily did not influence the pharmacokinetics of oral contraceptives (ethinylestradiol and levonorgestrel); endocrine parameters (luteinizing hormone and progesterone) were not modified. 
Levetiracetam primijenjen u dozi od 1000 mg na dan nije utjecao na farmakokinetiku oralnih kontraceptiva (etinil-estradiola i levonorgestrela); endokrini pokazatelji (luteinizirajući hormon i progesteron) ostali su nepromijenjeni.
Levetiracetam Teva contains Sodium 
Levetiracetam Teva sadrži natrij
305, 74770 Opava-Komarov 
Ostravska 29, c.p. 305, 74770 Opava-Komarov
A peri- and post-natal development study was performed in rats with levetiracetam doses of 70, 350 and 1800 mg/kg/day. 
Studija peri- i postnatalnog razvoja provedena je u štakora dozama levetiracetama od 70, 350 i 1800 mg/kg/dan.
In this study, levetiracetam dose was 3000 mg/day for adults and adolescents or 60 mg/kg/day for children, given in 2 divided doses. 
Doza levetiracetama u toj studiji bila je 3000 mg na dan za odrasle i adolescente, a za djecu 60 mg/kg/dan, podijeljena na dvije doze.
In this study, patients were prescribed 20 mg/kg, 25 mg/kg, 40 mg/kg or 50 mg/kg daily dose of oral solution based on their age titration schedule. 
U toj je studiji bolesnicima propisana oralna otopina u dnevnoj dozi od 20 mg/kg, 25 mg/kg, 40 mg/kg ili 50 mg/kg prema shemi titriranja ovisnoj o dobi.
Due to its complete and linear absorption, plasma levels can be predicted from the oral dose of levetiracetam expressed as mg/kg bodyweight. 
Uslijed potpune i linearne apsorpcije levetiracetama, moguće je na temelju oralne doze izražene u mg/kg tjelesne težine predvidjeti razinu lijeka u plazmi.
In infants and children aged 1 month to less than 4 years, irritability (very common, 11.7%) and coordination abnormal (common, 3.3%) were reported more frequently than in other age groups or in the overall safety profile. 
razdražljivost (vrlo često, 11,7%) i poremećaji koordinacije (često, 3,3%) bili su prijavljeni češće nego u drugim dobnim skupinama ili u cjelokupnom sigurnosnom profilu.
In all of the above cases an oral solution should be used. 
U svim tim slučajevima treba primijeniti oralnu otopinu.
Efficacy of levetiracetam as monotherapy was established in a double-blind, parallel group, non-inferiority comparison to carbamazepine controlled release (CR) in 576 patients 16 years of age or older with newly or recently diagnosed epilepsy. 
Djelotvornost levetiracetama za samostalno liječenje dokazana je kod paralelnih grupa u dvostruko slijepoj usporedbi neinferiornosti s karbamazepinom s kontroliranim otpuštanjem (CR, controlled release) na 576 bolesnika u dobi od 16 godina ili starijih s novo- ili nedavno dijagnosticiranom epilepsijom.